Patent details

LUC00325 Product Name: Tislélizumab

Basic Information

Publication number:
LUC00325
Type:
SPC
SPC Type:
Medical
Basic Patent Number:
EP201543865
Legal Status:
Inactive
Application number:
LUC00325
First applicant's nationality:
Procedural language:
French

Marketing Authorization

Marketing Authorization Number:
EU/1/23/1758
Marketing Authorization Type:
Marketing Authorization Date:
19/09/2023
Marketing Authorization Status:
Accepted
Marketing Authorization Country:
Luxembourg (LU)

Dates

Filing date:
12/12/2023
First Marketing Authorization date:
19/09/2023
Grant date:
02/02/2026
Activation date:
Publication date:
15/12/2023
Lapsed date:
Expiration date:
Renunciation date:
Revocation date:
Annulment date:
Basic SPC Expiration:
13/09/2038
SPC Extension Expiration:
13/09/2038
Rejection date:
Withdrawal date:

Owner

From:
21/08/2025
 
 

Name:
BeOne Medicines I GmbH
Address:
Aeschengraben 27, 4051, Basel, Switzerland (CH)

History of Owners

From:
12/12/2023
To:
21/08/2025

Name:
BeiGene Switzerland GmbH
Address:
Aeschengraben 27, 4051 Basel, Switzerland (CH)

Agent

Name:
OFFICE FREYLINGER S.A.
From:
12/12/2023
Address:
Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)
To:

Publication

Bulletin

1

Bulletin Heading:
SPC1
Bulletin edition number:
2024/01
Publication date:
05/01/2024
Description:
Section C : Published requests for Supplementary Protection Certificates – I1 publication

2

Bulletin Heading:
CO
Bulletin edition number:
2025/10
Publication date:
05/09/2025
Description:
Section M : Transfers of property (Art. 53 of the law), change of name and/or address

3

Bulletin Heading:
SPC2
Bulletin edition number:
2026/04
Publication date:
03/03/2026
Description:
Section D : Granted supplementary protection certificates – I2 publication

Deed

Change of owner(s)

Change Kind/ Decision Type:
Change of owner(s) name/address
Deed Number:
RC20250000298A
Date Registered:
21/08/2025
Licence Effective Date:
Licence Expiration Date:
Scope of Licence:
Deed Filer:
OFFICE FREYLINGER S.A.
Journal Edition Number:
Text:
Country Code:
Updated Licence Number:
Terminated Licence Number:

Added Owner(s)

Name:
BeOne Medicines I GmbH
Address:
Aeschengraben 27, 4051, Basel, Switzerland (CH)

Removed Pledgee

Name:
Address:

Annual Fees

Annual Fee Due Date:
30/09/2033
Annual Fee Number:
21
Annual Fee Amount:
410 Euro
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages
21/08/2025 Request For Change 4
22/08/2025 Outgoing Correspondence 1
12/12/2023 Summary of the product caracteristics 47
12/12/2023 Marketing authorization 3
12/12/2023 Application Form 3
12/12/2023 MA publication 10
15/12/2023 Outgoing Correspondence 1
15/12/2023 Publication 1
02/02/2026 Publication 1
02/02/2026 Outgoing Correspondence 1
02/02/2026 Certificate 1